Lentiviral vector transduced CD34+ cells 비교

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 2 Lentiviral vector transduced CD34+ cells (Lentiviral vector transduced CD34+ cells) Genetix Biotherapeutics Inc.·CD3 50 trials·t½ 16.2 h

Overview Program	Lentiviral vector transduced CD34+ cells
Overview Company	Genetix Biotherapeutics Inc.
Overview Modality	CGT
Overview Target	CD3
Overview Indication	P47-Phox, Deficiency of
Overview Phase	PHASE_2
Overview Status	ACTIVE
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

Technology Vector	lentiviral vector in nonhuman primates

MoA Mechanism	targeted CAR along with a rapamycin-activated cytokine receptor
MoA Biomarker	CD19, CD33, and CD123-to harbor a CD34-derived hinge region that allow

PK/PD Half-life	16.2 h
PK/PD Species	NHP, 2 h
PK/PD Animal (cat.)	NHP
PK/PD Experiment	pharmacokinetic

Toxicology Species	NHP, 2 h
Toxicology Animal (cat.)	NHP
Toxicology Major finding	thrombocytopenia were noted but not lymphopenia

Clinical Safety signal	thrombocytopenia were noted but not lymphopenia
Clinical Result source	ClinicalTrials.gov NCT02140554
Clinical Program phase	PHASE_2
Clinical Trial ref	NCT02140554

선택됨 (1/5)

추천 · 인기 프로그램

최대 5개 선택 · 전체 25+ 프로그램은 검색으로 찾을 수 있습니다. ADC 목록 →

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목	CGTStandard DatabasestalePhase 2 Lentiviral vector transduced CD34+ cells (Lentiviral vector transduced CD34+ cells) Genetix Biotherapeutics Inc.·CD3 50 trials·t½ 16.2 h

Overview Program	Lentiviral vector transduced CD34+ cells
Overview Company	Genetix Biotherapeutics Inc.
Overview Modality	CGT
Overview Target	CD3
Overview Indication	P47-Phox, Deficiency of
Overview Phase	PHASE_2
Overview Status	ACTIVE
Overview Content status	Standard Database
Overview Data Confidence	Data Confidence · Medium
Overview Development Signal	Development Signal · Emerging
Overview Approval status	Investigational

Technology Vector	lentiviral vector in nonhuman primates

MoA Mechanism	targeted CAR along with a rapamycin-activated cytokine receptor
MoA Biomarker	CD19, CD33, and CD123-to harbor a CD34-derived hinge region that allow

PK/PD Half-life	16.2 h
PK/PD Species	NHP, 2 h
PK/PD Animal (cat.)	NHP
PK/PD Experiment	pharmacokinetic

Toxicology Species	NHP, 2 h
Toxicology Animal (cat.)	NHP
Toxicology Major finding	thrombocytopenia were noted but not lymphopenia

Clinical Safety signal	thrombocytopenia were noted but not lymphopenia
Clinical Result source	ClinicalTrials.gov NCT02140554
Clinical Program phase	PHASE_2
Clinical Trial ref	NCT02140554